Estela Rodriguez, Associate Director of Community Outreach and Co-Lead of Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center, shared a post on X by Oncology Brothers, adding:
“Nice to finally see lung cancer on the NCCN list of cancers for which you could consider germline testing (up to 15% of patients who present with LC can have pathogenic variants) – it’s not for all, but there are patients and families that can benefit from germline testing.”
Quoting Oncology Brothers’ post.
“Current NCCN guidelines for germline testing.
This is one place where we collectively need to do better, not only to ensure we have the discussion for prescription options, but this has a profound impact on the patient’s family! ”
More from Estela Rodriguez on OncoDaily.